- SID Score
- 6.2/10
- Fair value
- $509.31
- Generated
- Nov 1, 2026
- Model
- claude-haiku-4-5-20251001
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is trading at $400.00 with a substantial market capitalization of $1.82 trillion, representing a convertible preferred stock offering positioned within the healthcare sector. The fair value estimate of $509.31 suggests 27.3% upside potential, though the current SID Score of 6.2/10 indicates moderate investment quality. With a P/E ratio of 17.28 and minimal dividend yield of 0.05%, this security appears moderately valued relative to its earnings generation capacity. The neutral news sentiment and "Hold" analyst consensus suggest cautious positioning rather than strong conviction in either direction.
The company exhibits mixed fundamental characteristics across key metrics, with Profitability and Growth grades both at C, indicating moderate performance without exceptional strength in either category. The Value grade of D suggests the security may not offer compelling value at current pricing levels relative to its asset base and earnings potential. Despite the substantial market capitalization, the lack of recent financial and earnings data limits comprehensive fundamental analysis, though the 27.3% upside to fair value indicates some analytical support for a higher valuation. The B-rated dividend profile suggests reasonable income characteristics for a preferred convertible security, though the 0.05% yield is minimal for income-focused investors.
Technical analysis for BMYMP is severely limited due to the absence of RSI(14), 50-day moving average, and 200-day moving average data, preventing assessment of momentum, trend direction, and price volatility patterns. Without these standard technical indicators, investors cannot determine whether the $400.00 price represents a breakout point, support level, or potential reversal zone. The C-rated Momentum grade suggests neutral price movement dynamics, but this assessment cannot be corroborated with traditional technical tools. Price action analysis and trend identification would require historical moving average data and relative strength measurements that are currently unavailable.
Analyst & Insider Sentiment
Recent insider activity reveals mixed signals with notable selling pressure from executive Bartie Wendy, who executed significant transactions on June 3, 2026, selling 20,121 shares while purchasing 15,957 shares in offsetting activity. Adam Lenkowsky's sales of 21,081 shares on May 1, 2026, further indicate insider sentiment leaning toward profit-taking or portfolio rebalancing rather than accumulation. The analyst consensus rating of "Hold" with unavailable price targets suggests professional investors lack conviction regarding significant upside or downside moves from current levels. These insider dispositions combined with neutral analyst sentiment suggest cautious optimism at best, with no strong catalysts identified for near-term appreciation.
The convertible preferred structure of BMYMP introduces complexity and layered risks including interest rate sensitivity, conversion risk, and subordination relative to senior debt in bankruptcy scenarios. The absence of recent financial data presents a significant analytical risk, as investors cannot properly assess balance sheet health, liquidity positions, or operational trends that might affect conversion probability or dividend security. The D-rated Value grade and modest 0.05% dividend yield suggest the security offers limited margin of safety, making it vulnerable to price depreciation if fundamentals deteriorate or market sentiment shifts. Healthcare sector volatility, regulatory risks, and Bristol-Myers Squibb's portfolio performance directly impact this preferred security's valuation and conversion probability.
BMYMP presents a moderate-risk opportunity for investors seeking healthcare exposure through a convertible preferred structure with 27.3% upside to fair value, though the "Hold" consensus and insider selling temper enthusiasm for aggressive accumulation. The security's fundamental metrics reveal balanced but unremarkable characteristics, with the C-rated profitability and growth grades suggesting stable but unexciting performance prospects. Income investors should note the minimal 0.05% dividend yield combined with the B dividend grade, indicating adequate but not exceptional income generation potential. Conservative investors should await clearer technical momentum, insider buying resumption, or improved analyst sentiment before initiating positions, while existing holders might consider maintaining positions given the fair value upside but trimming on strength given neutral sentiment signals.
